A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3X 2H9
- inVentiv Health Clinical
-
-
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Pinnacle Research Group; Llc, Central
-
Anniston, Alabama, United States, 36207
- Pinnacle Research Group Cullman
-
-
California
-
Coronado, California, United States, 92118
- Southern California Research Center, Inc.
-
Stanford, California, United States, 94305
- Stanford Health Care
-
Tustin, California, United States, 92780
- Diabetes Research Center
-
-
Florida
-
Hallandale Beach, Florida, United States, 33009
- MD Clinical
-
Miami, Florida, United States, 33165
- Premier Research Associate, Inc
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Agile Clinical Research Trials
-
-
Kansas
-
Overland Park, Kansas, United States, 66209
- Midwest Clinical Research
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Hassman Research Institute
-
-
North Carolina
-
Shelby, North Carolina, United States, 28150
- Carolina Research Center at Jones Family Practice
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- New Orleans Center for Clinical Research
-
-
Texas
-
Arlington, Texas, United States, 76012
- Texas Clinical Research Institute, LLC
-
Dallas, Texas, United States, 75230
- Dallas Diabetes & Endocrine Center
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas Incorporated
-
San Antonio, Texas, United States, 78249
- Northeast Clinical Research of San Antonio LLC
-
Shavano Park, Texas, United States, 78231
- Consano Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For T2DM Cohort only:
- Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m2.
- A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening
- Current stable treatment (at least 3 months) for diabetes
- Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0%.
- For women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug
- For men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm
- For NAFLD cohort only:
- BMI ≥ 25 kg/m2 and ≤ 40 kg/m2
- At screening, confirmed liver fat by ultrasound OR calculated Liver Fat ≥ 10% using variables from the NAFLD liver fat score
- Hepatic steatosis on magnetic resonance imaging (MRI; ≥ 10% average liver proton density fat fraction [PDFF]) prior to randomization.
Exclusion Criteria:
- Pregnant, lactating, or intending to become pregnant within 42 days after the last dose of study drug is administered
- Suspected or confirmed diagnosis of Type 1 diabetes
- Significant cardiac disease
- Any psychiatric illness that increases the risk of participation in the study
- History of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections
- Poor peripheral venous access
- Received blood products within 2 months before dosing
- Donation or loss of blood within 30-56 days prior to study drug administration
- Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody
- Liver enzymes greater than acceptable limits
- History of eating disorders or surgical procedures for weight loss
- Active participation in a structured weight loss or dietary program
- Treatment with investigational therapy or exposure to any biological therapy
- Illicit drug use, marijuana use, or alcohol abuse
- Current use of more than one pack of cigarettes a day or equivalent nicotine- containing products
- Any serious medical condition or abnormality in clinical laboratory tests
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Multiple Ascending Dose BFKB8488A
Participants will be randomized to receive BFKB8488A.
When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision.
This will be repeated for each cohort.
|
Administered subcutaneously starting on Day 1 and according to dosing schedule.
Other Names:
|
|
Placebo Comparator: Placebo
Participants will receive BFKB8488A-matching placebo.
|
Administered subcutaneously starting on Day 1 and according to dosing schedule.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants with Adverse Events (AE)
Time Frame: Up to 18 weeks following first dose administration
|
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
|
Up to 18 weeks following first dose administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum BFKB8488A Concentration
Time Frame: On multiple days during treatment period and follow-up (up to 18 weeks following first dose administration)
|
On multiple days during treatment period and follow-up (up to 18 weeks following first dose administration)
|
|
|
Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs)
Time Frame: On multiple days during treatment period and follow-up (up 18 weeks following first dose administration)
|
Participants are considered to be ATA positive if they are ATA negative at baseline but develop an ATA response following study drug administration (treatment-induced ATA response), or if they are ATA positive at baseline and at least one post-baseline samples if above acceptable limits.
The number and percentage of ATA-positive and ATA-negative participants will be summarized by treatment group.
|
On multiple days during treatment period and follow-up (up 18 weeks following first dose administration)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GC39547
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.